Woori Financial Group Inc. (KRX:316140) is now a materially bigger company than it was eighteen months ago, and almost none of that growth came from lending. Total assets stood at ₩525.8tn (~$376bn at roughly ₩1,400 to the dollar, a rough working rate) at the end of FY2024. By the second quarter of 2026 they were ₩635.2tn. That is about ₩110tn of new balance sheet in six quarters, and the bulk of it arrived through acquisition: Tongyang Life and ABL Life, the two insurers Woori bought to fix the one thing everyone says is wrong with it.
The thesis here is narrow. The deal has already done what a deal can do quickly, which is make the balance sheet look different. It has not yet done the harder thing, which is show up as durable profit. And the gap between those two facts is wider than the group's own framing suggests.
Insurance accounting under IFRS 17 puts a line called insurance service result on the income statement. It is the closest thing to an underwriting margin: premiums earned against claims and expenses incurred, stripped of the investment return. For Woori that line was zero through FY2023 and FY2024, because there was no insurer to consolidate. It appeared in FY2025 at ₩103.9bn.
Set that against what came with it. Woori's total assets grew ₩75.7tn in FY2025 alone. Total liabilities grew ₩73.7tn. For an insurer, most of that liability is policyholder reserve — money the group is on the hook for. So the first full year of owning insurers produced roughly ₩104bn of insurance service result against tens of trillions of new obligations. That ratio is not damning on its own. Life insurance is a long book and the reserve is supposed to be large relative to the annual margin. But it does mean the earnings case rests entirely on what happens over years, not on anything visible yet.
The quarterly path is less reassuring. Insurance service result ran ₩55.7bn in Q3 2025, ₩48.1bn in Q4 2025, ₩67.6bn in Q1 2026, then ₩15.9bn in Q2 2026. That last figure is a 76% drop from the prior quarter. The consolidated statements don't explain the fall, and I'm not going to invent a reason. Assumption changes, claims experience, a reserve true-up — any of those would do it. What matters is that four quarters in, this line is small and it moves a lot, which is the opposite of the stability a bank buys an insurer to get.
In August 2026 Woori moved to combine the two insurers rather than run them side by side. The board approved a comprehensive share exchange to take Tongyang Life fully in-house, and the completion filing was submitted to Korea's DART on 11 August. Press reports put the integration spend at around ₩300bn covering staff, strategy, finance and IT, with the combined entity holding roughly ₩55tn in assets. Those figures come from reporting, not from the filings I read, so treat them as approximate.
Integrations of this kind cost money before they save any. Woori's own numbers show the front end of that already. Selling, general and administrative expense went from ₩4,469.0bn in FY2024 to ₩5,179.6bn in FY2025, up 15.9%. Some of that is simply consolidating two more payrolls. Some of it is the work of merging them. Either way, group operating income fell to ₩3,674.8bn in FY2025 from ₩4,255.2bn, a 13.6% decline, even though net income edged up to ₩3,227.5bn from ₩3,171.5bn. When operating income drops and net income rises, the difference is coming from below the operating line, and an investor should want to know exactly where. The FY2025 pretax figure of ₩4,090.2bn against operating income of ₩3,674.8bn says a good deal of it sat in non-operating gains.
Strip out the acquisition noise and the engine is unchanged. Net interest income was ₩9,030.8bn in FY2025 against ₩8,886.3bn in FY2024. That is 1.6% growth. In the second quarter of 2026 it was ₩2,356.6bn versus ₩2,261.8bn a year earlier, up 4.2%. Meanwhile total assets grew about 19% over the same stretch. Spread income is not keeping pace with the balance sheet, which is what you'd expect when the added assets are insurance reserves rather than loans, but it also means the profit that funds the dividend is still coming from the same place it always did.
Fee income is the one genuinely encouraging line. Net fee and commission income reached ₩702.0bn in Q2 2026, up 34% from ₩522.3bn a year before, and ₩2,160.4bn for FY2025. Insurance distribution plausibly explains part of that. It is also the line where a bank-insurer combination should show up first, before underwriting margin, so this is the right place to look for early evidence the deal works.
Credit costs cut the other way. Provisions for credit losses were ₩2,102.8bn in FY2025 against ₩1,716.3bn in FY2024, a 22.5% increase. The quarterly run rate has since eased: ₩526.8bn in Q1 2026 and ₩439.2bn in Q2. Q2 net income of ₩1,026.5bn, up 9.24% year on year per the 24 July disclosure, owes something to that ₩88bn quarterly swing in provisioning. That is a real improvement and also a reversible one.
Woori's cancellation filing dated 24 July uses a reference close of ₩30,900 from the prior session, against 728,089,682 shares outstanding. That works out to roughly ₩22.5tn (~$16bn) of market value. Reported total equity at the end of Q2 2026 was ₩40.9tn, so the group trades near 0.55x book. Total equity includes non-controlling interests, so the multiple against common equity alone is somewhat different, but not enough to change the picture. Trailing four-quarter net income sums to about ₩3.30tn, putting the shares under 7x.
That is cheap even by the standards of Korean bank holdings, which have traded below book for most of a decade. The discount is the market saying it does not believe the insurance pivot yet either. Which cuts both ways: if the pivot does work, very little of that is in the price.
The honest counter is that four quarters is not long enough to judge a life insurer, and I'm partly judging noise. IFRS 17 recognizes profit as the contractual service margin releases over the life of the policy, so a newly consolidated book will show small service results for years while the value sits in the reserve. A one-quarter drop to ₩15.9bn could be an assumption update with no bearing on economics.
There is a capital argument too. Woori's CET1 ratio was reported at around 13.7% at the second quarter, per Korean press coverage of the earnings call — a level it did not have when it started this. A bank that consolidates ₩110tn of assets while capital ratios go up is doing something right in risk-weighted asset management, whatever the near-term earnings look like. And the non-bank contribution figure management cited, 6.9% rising to 22.3% of first-half group net income, is a real change in mix if the segment tables bear it out.
I'd also note a discrepancy worth flagging. Some coverage of the Q2 results described net income of about ₩1,551.3bn, down 11.6% year on year. The DART disclosure filed 24 July reports quarterly net income of ₩1,026.5bn, up 9.24%, and first-half net income of ₩1,666.0bn, up 4.5%. I don't know what basis produces the ₩1,551.3bn figure. Where they conflict, go with the filing.
Three things, all in the Q3 report. First, the insurance service result: does it recover toward the ₩50-70bn quarterly range, or was Q2's ₩15.9bn the start of a trend. Second, the segment disclosure behind the 22.3% non-bank contribution claim, and specifically how much of it is underwriting margin rather than investment income on the insurers' bond portfolios. Third, whether the ₩439.2bn provisioning run rate holds, because two quarters of that pace annualizes well below FY2025's ₩2.10tn and a large part of this year's earnings improvement depends on it staying there.
The merged insurer is meant to be operating as one entity from here. That gives a clean starting line. From Q3 onward there's no integration-in-progress excuse for a soft number.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.